Instrument Inactif

Communiqués AIT Therapeutics Inc Nasdaq

Actions

US0014481099

Equipement, fournitures et distribution médicale

Communiqués

02/09	Beyond Air to Participate in the 2026 Cantor Global Healthcare Conference	AQ
31/08	Beyond Air® Receives FDA Breakthrough Device Designation for LungFit® GO to Treat Nontuberculous Mycobacterial Pulmonary Disease (NTM-PD)	AQ
25/08	Beyond Air Enters Definitive Agreement to Sell Its NeuroNOS Stake to UNIVO Pharmaceutical Industries in Exchange for Equity and Milestone Payments	AQ
13/08	Beyond Air® Reports Financial Results for the Quarter Ended June 30, 2026 and Provides Corporate Update	AQ
04/08	Beyond Air Schedules Conference Call to Discuss Financial Results for the Quarter Ended June 30, 2026	AQ
30/07	Beyond Air® Announces Up to $30.1 Million Private Placement Offering Priced At-the-Market Under Nasdaq Rules	AQ
26/06	Beyond Air® Reports Fourth Quarter and Full Year 2026 Financial Results and Provides Corporate Update	AQ
22/06	Beyond Air Schedules Fiscal Year End 2026 Financial Results Conference Call and Webcast	AQ
10/06	Beyond Air, Inc. Urges Stockholders to Vote “FOR” All Proposals Ahead of the Upcoming Special Meeting	AQ
01/06	Beyond Air Receives Nasdaq Hearing Panel Decision Granting Continued Listing	AQ
20/04	Beyond Cancer Reports Updated Survival and Safety Data from Phase 1 UNO Trial Presented at AACR 2026	AQ
15/04	Beyond Air to Participate in the D. Boral Capital Global Conference 2026	AQ
02/04	Beyond Air Expands Commercial Access for LungFit PH through a Purchasing Agreement with a Top 3 National Group Purchasing Organization	AQ
01/04	Beyond Air Expands Commercial Access for LungFit® PH Through a Purchasing Agreement with a Top 3 National Group Purchasing Organization (GPO)	AQ
26/03	Beyond Air, Inc. Announces Resignation of Steve Lisi, CEO, and Appointment of Robert Goodman, Chief Commercial Officer, as CEO	AQ
17/03	Beyond Cancer Reports Early Clinical Activity and Favorable Safety Profile with Interim Data from Phase 1 UNO Trial	AQ
11/03	Beyond Air to Participate in the 38th Annual Roth Conference in March	AQ
10/03	Beyond Air® Announces Termination of Agreement to Sell Its NeuroNOS Subsidiary to XTL Biopharmaceuticals Ltd.	AQ
20/02	Beyond Air® Comments on Landmark Independent Review Article Highlighting the Antimicrobial Effects of High-Dose Inhaled Nitric Oxide and its Therapeutic Potential for Treating Respiratory Infections	AQ
13/02	Beyond Air® Reports Fiscal Third Quarter 2026 Financial Results and Provides Corporate Update	AQ
04/02	Beyond Cancer Abstract Featuring Phase 1 Data on Intratumoral Ultra-High Concentration Nitric Oxide (UNO) in Solid Tumor Metastases to be Presented at the AACR Annual Meeting 2026	AQ
27/01	Beyond Air to Participate in Two Upcoming Healthcare Investor Conferences	AQ
26/01	Beyond Air Schedules Third Fiscal Quarter 2026 Financial Results Conference Call and Webcast	AQ
14/01	Beyond Air Announces $5.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules	AQ
13/01	XTL Biopharmaceuticals Acquires 85% of Beyond Air’s Subsidiary NeuroNOS, Entering the Massive Autism Market with Nobel Prize-Winning Scientific Leadership	AQ